Cleared Traditional

K232084 - Stellaris Elite vision enhancement system

K232084 is an FDA 510(k) clearance for Stellaris Elite vision enhancement system, manufactured by Bausch and Lomb. The device is a Class 2 Ophthalmic device with product code HQC cleared through the Traditional 510(k) pathway after a 228-day FDA review.

K232084 · Bausch and Lomb · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2024
Decision
228d
Days
Class 2
Risk

K232084 is an FDA 510(k) clearance for the Stellaris Elite vision enhancement system. Classified as Unit, Phacofragmentation (product code HQC), Class II - Special Controls.

Submitted by Bausch and Lomb (St. Louis, US). The FDA issued a Cleared decision on February 26, 2024 after a review of 228 days - an extended review cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4670 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Bausch and Lomb devices

FDA 510(k) Submission Details - K232084

510(k) Number K232084 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 13, 2023
Decision Date February 26, 2024
Days to Decision 228 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
118d slower than avg
Panel avg: 110d · This submission: 228d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

HQC Device Classification - Class 2, Special Controls

Product Code HQC Unit, Phacofragmentation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4670
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - HQC Unit, Phacofragmentation

All 135
Devices cleared under the same product code (HQC) and FDA review panel - the closest regulatory comparables to K232084.
Stellaris Elite vision enhancement system (BL11145, BL14455, BL15455)
K240169 · Bausch and Lomb, Incorporated · Jul 2024
Faros Surgical System
K233398 · Oertli Instrumente AG · Jun 2024
UNITY VCS (8065000296)
K233876 · Alcon Laboratories, Inc. · Jun 2024
Centurion™ Vision System (Active Sentry™) (8065753057)
K233902 · Alcon Laboratories, Inc. · Jan 2024
QUATERA 700
K230858 · Carl Zeiss Meditec, AG · Jul 2023
MICOR Lens Fragmentation System
K214028 · Carl Zeiss Meditec Cataract Technology, Inc. · Sep 2022